Uniqure NV (NASDAQ:QURE) Director Philip Astley-Sparke sold 5,000 shares of the business’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $30.39, for a total transaction of $151,950.00. Following the completion of the transaction, the director now owns 23,252 shares in the company, valued at approximately $706,628.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
QURE opened at $29.95 on Friday. Uniqure NV has a 1-year low of $16.50 and a 1-year high of $43.23. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.56 and a current ratio of 7.56.
Uniqure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.03. Uniqure had a negative net margin of 725.04% and a negative return on equity of 58.49%. The firm had revenue of $3.15 million during the quarter, compared to the consensus estimate of $3.37 million. Equities research analysts predict that Uniqure NV will post -2.57 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC increased its stake in Uniqure by 16.6% in the second quarter. FMR LLC now owns 3,694,681 shares of the biotechnology company’s stock valued at $139,659,000 after purchasing an additional 526,283 shares in the last quarter. OppenheimerFunds Inc. bought a new stake in Uniqure in the second quarter valued at $63,553,000. Redmile Group LLC increased its stake in Uniqure by 1.0% in the third quarter. Redmile Group LLC now owns 1,639,900 shares of the biotechnology company’s stock valued at $59,676,000 after purchasing an additional 15,500 shares in the last quarter. Federated Investors Inc. PA increased its stake in Uniqure by 18.9% in the second quarter. Federated Investors Inc. PA now owns 1,091,280 shares of the biotechnology company’s stock valued at $41,250,000 after purchasing an additional 173,281 shares in the last quarter. Finally, Baker BROS. Advisors LP increased its stake in Uniqure by 21.0% in the second quarter. Baker BROS. Advisors LP now owns 605,000 shares of the biotechnology company’s stock valued at $22,869,000 after purchasing an additional 105,000 shares in the last quarter. 60.62% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently issued reports on QURE shares. Zacks Investment Research lowered shares of Uniqure from a “buy” rating to a “hold” rating in a report on Wednesday, October 17th. BidaskClub lowered shares of Uniqure from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. HC Wainwright set a $48.00 target price on shares of Uniqure and gave the company a “buy” rating in a report on Wednesday, November 7th. Chardan Capital boosted their target price on shares of Uniqure from $50.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, November 7th. Finally, B. Riley boosted their target price on shares of Uniqure from $50.00 to $72.00 and gave the company a “buy” rating in a report on Friday, November 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $55.67.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: Uniqure NV (QURE) Director Sells 5,000 Shares of Stock” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/12/08/insider-selling-uniqure-nv-qure-director-sells-5000-shares-of-stock.html.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Recommended Story: Cash Flow
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.